iRhythm Holdings, Inc.

iRhythm is a digital healthcare company providing device-based technology for ambulatory cardiac monitoring. Its offerings combine wearable, patch-based biosensors with cloud-based data analytic software to monitor patients and assist in diagnosing arrhythmias, such as atrial fibrillation. Key systems include the Zio monitor, Zio XT, and Zio AT systems, which support long-term continuous monitoring and mobile cardiac telemetry services. Customers and users primarily comprise physicians, cardiology practices, electrophysiologists, primary care clinicians, integrated delivery networks, and value-based healthcare organizations.

Headquartered in San Francisco, California, the company maintains independent diagnostic testing facilities in the United States and directly markets services domestically. Internationally, the company operates in the United Kingdom, Japan, and several European nations including Switzerland, Austria, the Netherlands, and Spain, utilizing direct sales teams and third-party distribution partners. As of late 2025, the company employed approximately 2,400 regular full-time employees and had processed over twelve million patient reports.

Summary of the business section of iRhythm's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had approximately 2,400 employees globally.”